MEAA Blood Coagulants Market to Post 9.5% CAGR till 2023 | with Pfizer Inc. (U.S.), Bayer AG, Novo Nordisk AS, Shire, SOBI, etc

MRFR Offers a Thorough Analysis of "ME&A Blood Coagulants Market 2019 ". The primary objective of the report is to analyse the current market landscape and its future potential. All the relevant parameters have been considered for market analysis. The report also includes a discussion on the growth opportunities, drivers and Restraints.

Middle East & Africa (MEA) Blood Coagulants Market is set to surge at a strong CAGR of 9.5% during the projected period (2017-2023). In addition, the market is anticipated to reach a valuation of more than 140 Mn towards 2023. Abnormal blood coagulation can have severe health impacts if not attended promptly. The condition literary means change of blood from liquid to gel, which subsequently causes blood clot.

Request Sample Copy at https://www.marketresearchfuture.com/sample_request/2743

Blood Coagulants Market: Competitive Landscape

Key players profiled in the global blood coagulants market include Novo Nordisk AS (Dernmark), Bayer AG (Germany), Octapharma (Switzerland), Shire (Republic of Ireland), CSL Limited (Australia), Pfizer Inc. (U.S.), and SOBI (Sweden).

The market for blood coagulation treatment in the MEA has been growing at a rampant pace. Driven by high prevalence of blood disorders and increased healthcare funding in several Middle Eastern countries, the market is likely to find significant growth opportunities in the coming years. Factors such as increased level of awareness about bleeding disorder, improving reimbursement programs and introduction of favorable policies for the healthcare sector in the region is expected to support the growth of the market.

Major transformations have taken psegmentslace in the healthcare sector present in MEA, with GCC countries such UAE, Qatar, Saudi Arabia at the forefront. Significant amount of investments has been made in recent years to improve the healthcare services across the region. This is partly supporting the growth of the blood coagulants market in the region. Moreover, factors such as higher penetration of healthcare services, increased healthcare expenditure and availability of advanced healthcare support are also propelling the market forward. Nevertheless, there are certain barriers that limit the market to reach its full potential. Extensive reliance on foreign-based healthcare services, poor R&D landscape in the domestic pharmaceutical industry and influx of counterfeit drugs pose major challenges to the market. At the same time, the development in the region is unequal from county to country and even city to city, which creates a contrasting market reflection.

Segments:

The report includes a comprehensive segmental analysis of the market based on indication, type and country. Based on indication, the market has been segmented into other bleeding disorders, haemophilia, and surgery and other.  The haemophilia segment is further sub-segment into haemophilia B and haemophilia A. The haemophilia segment is expected to remain highly attractive throughout the assessment period. Currently, the segment accounts for close 46% share of the market in terms of value. In the year 2016, the segment surpassed a market valuation of USD 30 Mn.  By type, the market has been segmented into coagulation factor and others. The coagulation factor segment is further sub-segment into plasma coagulation factor, recombinant coagulation factor and others.

Regional Analysis:

The market for blood coagulation in the Middle East & Africa has been covered across Qatar, Saudi Arabia (KSA), Kuwait, United Arab Emirates (UAE), Egypt, Oman, and Rest of MEA. Among these, the market in Saudi Arabia is likely to exhibit a relatively higher growth during the forecast period. The country accounted for the lion’s share of the market in 2016. This is primarily owing to the existence of a large patient pool along with the accessibility to an adequate healthcare system. Furthermore, factors such as rising incidences of haemophilia and widespread availability of blockbuster drugs are proving an impetus to the market in the country. The country is also witnessing an improvement in standard of living owing rising per capita income, which also favours the pharmaceutical sector present in Saudi Arabia. Meanwhile, the market in UAE is also projected to post a strong growth over the next couple years, capturing 10.1% CAGR between 2017 and 2023.

Browse Complete 53 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.